Key result
Intravenous pimobendan acted as a stronger arterio-venodilator than oral captopril, producing marked pulmonary and venous dilation in addition to comparable systemic vasodilation in patients with chronic heart failure.
Why the study?
Does pimobendan improve acute hemodynamics compared to captopril in patients with chronic heart failure?
Does pimobendan improve acute hemodynamics compared to captopril in patients with chronic heart failure?
In patients with chronic heart failure, intravenous pimobendan acts as a stronger arterio-venodilator than oral captopril, producing marked pulmonary arteriovasodilating and venodilating effects.
Answers are grounded in this paper and cite their sources.
May support acute IV use in chronic HF; leaves open outcome trials before practice change.
Acute hemodynamics of pimobendan were compared to captopril in a crossover trial in patients with chronic heart failure (NYHA II-III). Heart failure had been stabilized by conventional therapy with diuretics and digitalis for more than 2 weeks. Patients receiving vasodilators were excluded. The hemodynamics were analyzed using a Swan-Ganz catheter at the bedside during drug administration. Following an intravenous injection of 2.5 mg of pimobendan, there was a significant increase in heart rate and decrease in mean pulmonary artery pressure, total pulmonary resistance, mean arterial pressure, systemic vascular resistance and mean right atrial pressure 2 hours after the injection. Captopril (12.5 mg, orally) significantly decreased mean arterial pressure, systemic vascular resistance and double product 2 hours after administration. In this study, the inotropic effect was evaluated through the relation between the stroke volume index and diastolic pulmonary artery pressure, and also between the stroke volume index and mean arterial pressure. Although decreases of diastolic pulmonary artery pressure and mean arterial pressure were seen with both drugs, the differences in stroke volume index were not significant. In comparison with captopril, the acute hemodynamics of pimobendan are characterized as follows: 1) the systemic arteriovasodilating effects of the two drugs were equal, 2) the pulmonary arteriovasodilating effect of pimobendan was marked, 3) a venodilating effect, documented through a decrease of mean right atrial pressure, was seen only with pimobendan. This study concluded that pimobendan is a stronger arterio-venodilator than captopril.
No takes yet. Share an insight, caveat, or question.
Tsuda et al. (1992) studied Chronic heart failure (n=10). Pimobendan vs. Captopril 12.5 mg orally was evaluated on Systemic vascular resistance (SVR) at 2 hours (dyne·sec·cm-5) (p=<0.01). Intravenous pimobendan acted as a stronger arterio-venodilator than oral captopril, producing marked pulmonary and venous dilation in addition to comparable systemic vasodilation in patients with chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: